论文部分内容阅读
目的探讨膀胱尿路上皮癌中Livin蛋白的表达情况及其临床意义。方法应用免疫组化Super Vision(SV)两步法检测Livin蛋白在86例膀胱尿路上皮癌组织(A)及其癌旁非癌组织(B)和20例正常膀胱黏膜组织(C)中的表达情况,并分析其与膀胱尿路上皮癌临床病理特征的关系。结果 Livin蛋白在ABC中的阳性表达率分别为67.4%(58/86),3.5%(3/86),0(0/20),AB和AC均有统计学差异(P<0.01),BC无统计学差异(P>0.05);Livin蛋白与膀胱尿路上皮癌是否复发相关(P<0.05),而与性别、年龄、肿瘤数目、组织学分级、临床病理分期、淋巴结转移与否等无关(P>0.05)。结论 Livin可能在某些环节参与了膀胱尿路上皮癌的发生及复发,有望成为膀胱尿路上皮癌早期诊断、监测复发的瘤标之一。
Objective To investigate the expression of Livin protein in bladder urothelial carcinoma and its clinical significance. Methods The expression of Livin protein in 86 cases of bladder urothelial carcinoma (A) and its adjacent non-cancerous tissues (B) and 20 cases of normal bladder mucosa (C) was detected by immunohistochemistry Super Vision (SV) Expression, and analysis of its relationship with the clinicopathological features of bladder urothelial carcinoma. Results The positive rates of Livin protein in ABC were 67.4% (58/86), 3.5% (3/86) and 0 (0/20), respectively. There was a significant difference between AB and AC (P <0.01) (P <0.05). There was no correlation between Livin protein and bladder urothelial carcinoma (P <0.05), but not with sex, age, tumor number, histological grade, clinical stage and lymph node metastasis (P> 0.05). Conclusions Livin may be involved in the occurrence and recurrence of bladder urothelial carcinoma in some aspects and is expected to be one of the tumor markers for early diagnosis and recurrence of urothelial carcinoma.